Fact sheet: Candriam Eq L Btchnlg

Fund information
Fund name
Candriam Equities L Biotechnology N USD
Fund manager company
Candriam Luxembourg
Fund type
Offshore Fund
Fund manager
  • Rudi VAN DEN EYNDEsince 05/04/2000
Fund objective
The subfund invests in biotechnology companies and in related activities (e.g. molecular diagnostics & scientific equipment). It has a worldwide scope but given the innovative history of the US biotechnology sector, most of the assets are invested in the US. The fund is not managed against a specific benchmark.
Benchmark
No data available.
Investment style
Growth
Investment method
Shares
Quick stats
1 Year return
21.3%
1 Year rank in sector
7/31
Sector
FO Equity - Pharma Health & Biotech
Yield
-
Ongoing charge (OCF)
?A fund’s ongoing charges figure (OCF) is similar to the old-style total expense ratio. It reflects the annual charge to investors in the fund, in percentage terms, but does not include extra performance-related fees (where these are levied) or the fund’s trading expenses on its underlying investments.
2.3%
Fund size
£632m (£487m last year)
FE Risk score
?FE Risk Scores measure the riskiness of instruments relative to the FTSE 100 index of shares. Weekly volatility is measured over three years with recent behaviour counting more heavily than earlier behaviour. Cash-type investments will have scores close to zero. Funds will tend to have scores in the 0-150 range. The FTSE 100 is always scored at 100. There is no upper limit.
220
Top in this sector
Fund name1 Year
Polar Capital Biotechnology32.4%
Pictet Biotech31.4%
Franklin Biotech Disc25.1%
BB Medtech23.3%
UBS (L)E-Btech$23.2%
...more in FO Equity - Pharma Health & Biotech

Performance snapshot

Holdings snapshot

Performance vs Sector

Cumulative performance
 1 mth3 mth6 mth1 yr3 yr5 yr
Fund2.7%8.9%0.4%21.3%18.5%140.4%
Sector0.6%9.1%1.2%14.1%25.1%105.2%
Rank within sector3 / 3112 / 3120 / 317 / 3117 / 274 / 24
Quartile1st2nd3rd1st3rd1st
Calendar performance
 YTD - 20172016201520142013
Fund11.4%-19.9%7.6%34.9%63.8%
Sector9.3%-9.9%7.2%28.1%41%
Rank within sector10 / 3128 / 3117 / 2910 / 263 / 24
Quartile2nd4th3rd2nd1st
Risk statistics
Alpha
?Alpha is a measure of a fund's over- or under-performance by comparison to its benchmark. If the Alpha is 5, the fund has outperformed its benchmark by 5%; so the greater the Alpha, the greater the outperformance.
-4.1
Beta
?Beta estimates a fund's volatility by comparison to that of its benchmark. A fund with a beta close to 1 means that the fund will move generally in line with the benchmark. Higher than 1 and the fund is more volatile than the benchmark and vice versa.
1.56
Sharpe
?This commonly-used measure calculates the level of return over and above the return of a notional risk-free investment, such as cash. The difference in returns is then divided by the fund's volatility. The resulting ratio is an indication of the amount of excess return generated per unit of risk.
0.02
Volatility
?Volatility (or standard deviation), when applied to an investment fund, expresses its risk. It shows how widely a range of returns varied from the fund's average return over a particular period. For example, if a fund had an average return of 5%, and its volatility was 15, this would mean that the range of its returns over the period had swung between +20% and -10%.
27.32
Tracking error
?This measures the standard deviation of a fund's excess returns over the returns of an index or benchmark portfolio. As such, it can be an indication of 'riskiness' in the manager's investment style. A Tracking Error below 2 suggests a passive approach. At 3 and above the the manager will be deploying a more active investment style.
14.14
Information ratio
?This is a useful risk-adjusted measure of actively managed fund performance. It is calculated by deducting the returns of the fund's benchmark from the fund's overall returns, then dividing the result by its tracking error. The higher the Information Ratio the better. It is generally considered that a figure of 0.5 reflects a good performance, 0.75 very good, and 1.00 outstanding.
-0.17
R-Squared
?An indication of how closely correlated a fund is to an index or a benchmark. Values for R-Squared range between 0 and 1, with 0 indicating no correlation at all and 1 showing a perfect match. Values upwards of 0.7 suggest that the fund's behaviour is increasingly linked to its benchmark.
0.85
Price movement
52 week high382.21
52 week low289.62
Current bid price-
Current offer price-
Current mid price364.79
Region
1USA89.03%
2Others8.57%
3UK2.4%
Industry sector
1Biotechnology/Medical99.73%
2Others0.27%
Asset type
1International Equities96.75%
2Others3.25%
Individual holdings
1GILEAD SCIENCES INC7.41%
2INCYTE CORP7.3%
3AMGEN INC6.5%
4BIOGEN INC6.28%
5REGENERON PHARMACEUTICALS INC5.72%
6CELGENE CORP5.57%
7ALEXION PHARMACEUTICALS INC3.31%
8VERTEX PHARMACEUTICAL2.82%
9TESARO INC2.53%
Management
Fund manager group
Dexia Asset Management
Fund manager company
Candriam Luxembourg
Fund type
Offshore Fund
Fund objective
The subfund invests in biotechnology companies and in related activities (e.g. molecular diagnostics & scientific equipment). It has a worldwide scope but given the innovative history of the US biotechnology sector, most of the assets are invested in the US. The fund is not managed against a specific benchmark.
Benchmark
No data available.
Investment style
Growth
Investment method
Shares
Fund manager
NameSinceBiography
Rudi VAN DEN EYNDE05/04/2000
Compliance
Transparent for Austrian Tax, Transparent for Swiss Tax, IA Recognised, Reporting Fund Status, UCITS IV Compliant
Domicile
No data available.
Fund for sale in
Austria, Belgium, Switzerland, Germany, Denmark, Spain, Finland, France, United Kingdom, Italy, Luxembourg, Netherlands, Offshore, Portugal, Singapore, Sweden
Candriam Equities L Biotechnology C Cap USD
Initial charge3.5%
Annual charge1.5%
Min single investment£0
Min regular saving£0
Available in ISANo
Ongoing charge (OCF)1.84%
Total expense ratio (TER)-
Bid price-
Offer price-
Mid price492.75
CurrencyUSD
Price updated21/03/2017
TypeAccumulation
Institutional or retail classRetail
Domicile-
Citi codeBI82
Candriam Equities L Biotechnology C EUR
Initial charge-
Annual charge-
Min single investment£0
Min regular saving£0
Available in ISANo
Ongoing charge (OCF)1.88%
Total expense ratio (TER)-
Bid price-
Offer price-
Mid price87.65
CurrencyEUR
Price updated05/11/2007
TypeAccumulation
Institutional or retail classRetail
Domicile-
Citi codeY519
Candriam Equities L Biotechnology C Hedged Cap EUR
Initial charge3.5%
Annual charge1.5%
Min single investment£0
Min regular saving£0
Available in ISANo
Ongoing charge (OCF)1.8%
Total expense ratio (TER)-
Bid price-
Offer price-
Mid price138.23
CurrencyEUR
Price updated22/03/2017
TypeAccumulation
Institutional or retail classRetail
Domicile-
Citi codeFRAO
Candriam Equities L Biotechnology C U Cap EUR
Initial charge3.5%
Annual charge1.5%
Min single investment£0
Min regular saving£0
Available in ISANo
Ongoing charge (OCF)1.86%
Total expense ratio (TER)-
Bid price-
Offer price-
Mid price130.61
CurrencyEUR
Price updated22/03/2017
TypeAccumulation
Institutional or retail classRetail
Domicile-
Citi codeFULD
Candriam Equities L Biotechnology D Dis USD
Initial charge3.5%
Annual charge1.5%
Min single investment£0
Min regular saving£0
Available in ISANo
Ongoing charge (OCF)1.88%
Total expense ratio (TER)-
Bid price-
Offer price-
Mid price475.52
CurrencyUSD
Price updated22/03/2017
TypeIncome
Institutional or retail classRetail
Domicile-
Citi codeBI81
Candriam Equities L Biotechnology D EUR
Initial charge-
Annual charge-
Min single investment£0
Min regular saving£0
Available in ISANo
Ongoing charge (OCF)1.88%
Total expense ratio (TER)-
Bid price-
Offer price-
Mid price86.36
CurrencyEUR
Price updated05/11/2007
TypeIncome
Institutional or retail classRetail
Domicile-
Citi codeY518
Candriam Equities L Biotechnology I Cap EUR
Initial charge-
Annual charge0.45%
Min single investment£250,000
Min regular saving£0
Available in ISANo
Ongoing charge (OCF)0.59%
Total expense ratio (TER)-
Bid price-
Offer price-
Mid price1271.05
CurrencyEUR
Price updated22/03/2017
TypeAccumulation
Institutional or retail classInstitutional
Domicile-
Citi codeFWAO
Candriam Equities L Biotechnology I Hedged Cap EUR
Initial charge-
Annual charge0.45%
Min single investment£250,000
Min regular saving£0
Available in ISANo
Ongoing charge (OCF)0.59%
Total expense ratio (TER)-
Bid price1389.69
Offer price1389.69
Mid price-
CurrencyEUR
Price updated22/03/2017
TypeAccumulation
Institutional or retail classInstitutional
Domicile-
Citi codeE2KE
Candriam Equities L Biotechnology I U Cap GBP
Initial charge-
Annual charge0.45%
Min single investment£250,000
Min regular saving£0
Available in ISANo
Ongoing charge (OCF)0.59%
Total expense ratio (TER)-
Bid price-
Offer price-
Mid price2005.17
CurrencyGBP
Price updated22/03/2017
TypeAccumulation
Institutional or retail classInstitutional
Domicile-
Citi codeE7OT
Candriam Equities L Biotechnology I USD
Initial charge-
Annual charge0.75%
Min single investment£250,000
Min regular saving£0
Available in ISANo
Ongoing charge (OCF)0.89%
Total expense ratio (TER)-
Bid price-
Offer price-
Mid price3233.44
CurrencyUSD
Price updated22/03/2017
TypeAccumulation
Institutional or retail classInstitutional
Domicile-
Citi codeQF08
Candriam Equities L Biotechnology L USD
Initial charge3.5%
Annual charge1.5%
Min single investment£0
Min regular saving£0
Available in ISANo
Ongoing charge (OCF)2.01%
Total expense ratio (TER)-
Bid price-
Offer price-
Mid price490.61
CurrencyUSD
Price updated22/03/2017
TypeAccumulation
Institutional or retail classRetail
Domicile-
Citi codeNFB4
Candriam Equities L Biotechnology N EUR
Initial charge-
Annual charge2%
Min single investment£0
Min regular saving£0
Available in ISANo
Ongoing charge (OCF)2.3%
Total expense ratio (TER)-
Bid price-
Offer price-
Mid price67.28
CurrencyEUR
Price updated05/11/2007
TypeAccumulation
Institutional or retail classRetail
Domicile-
Citi codeY517
Candriam Equities L Biotechnology N USD
Initial charge-
Annual charge2%
Min single investment£0
Min regular saving£0
Available in ISANo
Ongoing charge (OCF)2.3%
Total expense ratio (TER)-
Bid price-
Offer price-
Mid price364.79
CurrencyUSD
Price updated22/03/2017
TypeAccumulation
Institutional or retail classRetail
Domicile-
Citi codeQF07
Candriam Equities L Biotechnology R Cap USD
Initial charge3.5%
Annual charge0.75%
Min single investment£0
Min regular saving£0
Available in ISANo
Ongoing charge (OCF)1.02%
Total expense ratio (TER)-
Bid price-
Offer price-
Mid price148.84
CurrencyUSD
Price updated22/03/2017
TypeAccumulation
Institutional or retail classRetail
Domicile-
Citi codeFE8K
Candriam Equities L Biotechnology R Hedged Cap CHF
Initial charge3.5%
Annual charge0.75%
Min single investment£0
Min regular saving£0
Available in ISANo
Ongoing charge (OCF)1.05%
Total expense ratio (TER)-
Bid price-
Offer price-
Mid price139.85
CurrencyCHF
Price updated22/03/2017
TypeAccumulation
Institutional or retail classRetail
Domicile-
Citi codeC05B
Candriam Equities L Biotechnology R U Cap EUR
Initial charge3.5%
Annual charge0.75%
Min single investment£0
Min regular saving£0
Available in ISANo
Ongoing charge (OCF)1.05%
Total expense ratio (TER)-
Bid price-
Offer price-
Mid price181.35
CurrencyEUR
Price updated22/03/2017
TypeAccumulation
Institutional or retail classRetail
Domicile-
Citi codeE7OR
Candriam Equities L Biotechnology R U Cap GBP
Initial charge3.5%
Annual charge0.75%
Min single investment£0
Min regular saving£0
Available in ISANo
Ongoing charge (OCF)1.05%
Total expense ratio (TER)-
Bid price-
Offer price-
Mid price202.54
CurrencyGBP
Price updated22/03/2017
TypeAccumulation
Institutional or retail classRetail
Domicile-
Citi codeE7OS
Candriam Equities L Biotechnology V Acc USD
Initial charge-
Annual charge0.45%
Min single investment£15,000,000
Min regular saving£0
Available in ISANo
Ongoing charge (OCF)0.59%
Total expense ratio (TER)-
Bid price-
Offer price-
Mid price1171.79
CurrencyUSD
Price updated22/03/2017
TypeAccumulation
Institutional or retail classInstitutional
Domicile-
Citi code0DQQ
Candriam Equities L Biotechnology Z Acc USD
Initial charge-
Annual charge-
Min single investment£0
Min regular saving£0
Available in ISANo
Ongoing charge (OCF)0.14%
Total expense ratio (TER)-
Bid price-
Offer price-
Mid price1215.16
CurrencyUSD
Price updated22/03/2017
TypeAccumulation
Institutional or retail classInstitutional
Domicile-
Citi codeGGXV
Data provided by

The Content is only for your general information and use and is not intended to address your particular requirements. The Content does not constitute any form of advice, recommendation or arrangement by Moneywise and is not intended to be relied upon by you in making (or refraining from making) any specific investment or other decisions. Appropriate independent advice should be obtained before making any such decision.

This information is sourced from our partner Financial Express. We believe the data to be correct however you should take care in using any information.

You should be aware that prices may fall as well as rise and that the income derived can go down as well as up. When buying or selling any investment that fluctuates in price or value you may get back less than you invested. Past performance is not necessarily a guide to future performance.